AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary results of studies that suggest their TROP2-targeted antibody-drug conjugates (ADCs) could have a
AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –
The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market
The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the cha
Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed b
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.